MedTrace Logo

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

NCT05461794 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-06-13

Study results available
· View outcomes & findings →

Summary

The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who experienced disease progression following prior systemic chemotherapy.

Conditions

Interventions

DRUG

Sitravatinib

100 mg orally once daily

DRUG

Tislelizumab

200 mg intravenously once every 3 weeks

DRUG

Docetaxel

75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle

DRUG

Irinotecan

125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2024-02-26
Completion
2024-02-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461794 on ClinicalTrials.gov